Revolutionary MINT Technology
MINT, an innovative stent-free platform developed for glaucoma angle surgery in adult patients, represents a significant advancement in medical device technology. The system leverages sophisticated mechanical, semi-automated trephination technology, achieving unprecedented precision with its 0.14 mm cutting-edge diameter to create optimal openings in the pigmented trabecular meshwork.
Key Features
- Stent-free platform
- Semi-automated trephination
- 0.14 mm cutting-edge precision
- Minimally invasive approach
Clinical Benefits
- Optimal trabecular meshwork opening
- Enhanced surgical precision
- Reduced medication dependency
- Improved patient outcomes
Clinical Evidence & Expert Perspective
"MINT represents a substantial transformation in the field of minimally invasive glaucoma surgery (MIGS), with significant potential to improve patient outcomes and elevate the standard of care. Clinical data from our prospective, single-arm study with a two-year follow-up indicate that MINT is both safe and effective in lowering intraocular pressure (IOP), while also reducing the need for glaucoma medications."
The Tel Aviv-based medical device company Sanoculis has strategically positioned this breakthrough technology to transform the standard of care in glaucoma treatment. As leading medical device companies continue to expand their portfolios, this stent-free approach offers compelling advantages in terms of both clinical efficacy and minimally invasive methodology.
European MIGS Market Landscape
Key Market Players
- Bausch+Lomb (Recent acquisition of Elios Vision)
- Glaukos (iDose TR system)
- iStar (MINIject technology)
- Sanoculis (MINT platform)
Commercial Strategy & Opportunities
Strategic Initiatives
- Selective pre-launch planned for later this year
- Creation of specialized sales positions
- Expanding market presence in Europe
- Building partnerships with key stakeholders
The CE mark approval validates MINT's potential to address unmet needs in glaucoma treatment, positioning Sanoculis as an emerging leader in the ophthalmology medical device sector. This development signals promising opportunities for stakeholders across the medical device industry, from investors to sales professionals.